PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells

Arrighetti, Noemi; Cossa, Giacomo; Cecco, Loris De; Stucchi, Simone; Carenini, Nives; Corna, Elisabetta; Gandellini, Paolo; Zaffaroni, Nadia; Perego, Paola; Gatti, Laura

doi:10.1016/j.taap.2016.08.005

Cited by 38 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But in our results, the inhibition of miR-483-3p had no effect on migration and cell proliferation, which may be that the pathways regulating drug resistance are multiple and complex. Conversely, sensitivity to oxaliplatin was further enhanced upon overexpression of miR-483-3p in HCT116/L cells, which was contrary to previous studies [18]. The reason may be that miR-483-3p has specific functions in complex cancer types, or that cancer resistance is regulated by multiple miRNAs at the same time.…”

Section: Discussioncontrasting

confidence: 83%

“…In this study, we comparatively assessed differentially expressed miRNAs and genes of HCT116 and HCT116/L cells with the final aim of clarifying the miRNAs and their target genes associated with oxaliplatin resistance. Previous studies have suggested that miR-483-3p was dysregulated in some types of tumours [17][18][19]. However, the mechanisms by which miR-483-3p is associated with oxaliplatin resistance in CRC are largely unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

Liang

Qiang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Oxaliplatin resistance limits the efficiency of treatment for colorectal cancer (CRC). Studies have shown that abnormal expression of microRNAs (miRNAs) were associated with tumorigenesis, cancer development and chemoresistance. The purpose of this study was to identify potential miRNAs related to oxaliplatin resistance in CRC cells. In this work, using small RNA sequencing (small RNA-Seq) and transcriptome sequencing (RNA-Seq), we found that down-regulated miR-483-3p was concurrent with up-regulated FAM171B in oxaliplatin-resistant colorectal cancer cell line HCT116/L as compared with its parental cell line HCT116. Transient transfection of miR-483-3p mimics markedly decreased the levels of FAM171B and restored oxaliplatin responsiveness of HCT116/L cells, and this alteration enhanced cell apoptosis and weakened cell migration. Whereas miR-483-3p inhibitor dramatically promoted the expression of FAM171B and enhanced oxaliplatin resistance of HCT116 cells by repressing cell apoptosis. Furthermore, knockdown of FAM171B in HCT116/L cells could also sensitize its reaction of the treatment with oxaliplatin, which was verified by the reduced cell migration. These findings demonstrate that FAM171B is a functional target of miR-483-3p in the regulation of oxaliplatin resistance in human CRC cells.

show abstract

Section: Discussioncontrasting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

Liang

Qiang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Many miRNAs identified as dysregulated in the present study have also been reported as altered in other cancer types, including breast cancer (miR‐374b‐5p, miR‐429, miR‐200b‐5p, miR‐200b‐3p, miR‐187‐3p, miR‐196a‐5p, miR‐183‐5p, miR‐21‐5p, and miR‐182‐5p); gastric cancer (miR‐374b‐5p, miR‐200c‐3p, miR‐18b‐5p, miR‐196a‐5p, miR‐21‐5p, and miR‐20a‐3p); ovarian cancer (miR‐141‐5p, miR‐182‐5p, miR‐483‐3p, and miR‐200c‐3p); hepatocellular carcinoma (miR‐135a‐5p, miR‐187‐3p, miR‐148a‐5p, miR‐200a‐3p, and miR‐9‐3p); colorectal cancer (miR‐9‐3p, miR‐135a‐5p, miR‐200c‐3p, miR‐200b‐3p, and miR‐182‐5p); thyroid cancer (miR‐7‐5p and miR‐9‐3p); lung cancer (miR‐200b‐5p, miR‐200b‐3p, miR‐9‐5p, miR‐200a‐3p, and miR‐21‐5p); pancreatic cancer (miR‐200b‐3p, miR‐483‐3p, and miR‐183‐5p); chronic lymphocytic leukemia (miR‐4521, miR‐7‐5p, and miR‐182‐5p); Hodgkin lymphoma (miR‐876‐5p); cervical cancer (miR‐429); head and neck squamous cell carcinoma (miR‐200b‐5p); and bladder cancer (miR‐148a‐3p) …”

Section: Discussionsupporting

confidence: 65%

“…-5p)[39][40][41][42][43][44][45][46] ; gastric cancer (miR-374b-5p, miR-200c-3p, miR-18b-5p, miR-196a-5p, miR-21-5p, and miR-20a-3p)[47][48][49][50][51] ; ovarian cancer (miR-141-5p, miR-182-5p, miR-483-3p, and miR-200c-3p)[52][53][54][55] ; hepatocellular carcinoma (miR-135a-5p, miR-187-3p, miR-148a-5p, miR-200a-3p, and miR-9-3p)[56][57][58][59] ; colorectal cancer…”

mentioning

confidence: 99%

Candidate diagnostic miRNAs that can detect cancer in prostate biopsy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…miR-483 was initially identified in the human fetal liver (16) and is located within intron 2 of the insulin-like growth factor 2 locus (17). It serves important roles in the mechanism of many diseases, including alcoholic hepatitis (18), diabetic cardiomyopathy (19), ovarian carcinoma (20) and pancreatic cancer (21). In the present study, the effect of miR-483-3p in breast cancer was investigated and the results demonstrated that miR-483-3p was downregulated in breast cancer cell lines, especially in MCF7 cells.…”

Section: Discussionmentioning

confidence: 99%

Tumor suppressor function of miR‑483‑3p on breast cancer via targeting of the cyclin E1 gene

Huang

Jin

2018

Exp Ther Med

View full text Add to dashboard Cite

microRNA (miR)-483-3p has previously been demonstrated to be a tumor suppressor in many types of cancer cells, however it is unknown whether miR-483-3p is involved in the regulation of breast cancer. Therefore, the aim of the present study was to investigate the effects of miR-483-3p on breast cancer. The results demonstrated that the expression of miR-483-3p was decreased, especially in MCF-7 cells. The results of CCK-8 assay and cell cycle analysis demonstrated that miR-483-3p significantly reduced cell proliferation and inhibited MCF-7 cells in the G1 phase from entering the S phase (P<0.01). It was also demonstrated that Cyclin E1 (CCNE1) is a target gene of miR-483-3p using bioinformatics and a dual luciferase reporter assay. miR-483-3p inhibited the expression of CCNE1, cyclin-dependent kinase 2, nuclear protein ataxia-telangiectasia (NPAT) and phosphorylated NPAT. Therefore, the results indicated that miR-483-3p functions as a tumor suppression in breast cancer and CCNE1 is its target gene. Downstream genes of CCNE1 were also repressed by miR-483-3p. Therefore, these findings suggest that miR-483-3p is a key factor in breast cancer.

show abstract

PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells

Cited by 38 publications

References 44 publications

MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

Candidate diagnostic miRNAs that can detect cancer in prostate biopsy

Tumor suppressor function of miR‑483‑3p on breast cancer via targeting of the cyclin E1 gene

Contact Info

Product

Resources

About